Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

Seth J Baum,1,2 Rolin L Wade,3 Pin Xiang,4 Jorge Arellano,4 Cesar Cerezo Olmos,5 Sasikiran Nunna,6 Chi-Chang Chen,6 Cathryn M Carter,7 Nihar R Desai8 1Department of Integrated Medical Sciences, Charles E Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA; 2Preventive Cardi...

Full description

Bibliographic Details
Main Authors: Baum SJ, Wade RL, Xiang P, Arellano J, Cerezo Olmos C, Nunna S, Chen CC, Carter CM, Desai NR
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:Therapeutics and Clinical Risk Management
Subjects:
cardiovascular risk
lipid-lowering therapy
low-density lipoprotein
pcsk9 inhibitor
real-world treatment patterns
Online Access:https://www.dovepress.com/demographic-and-clinical-characteristics-of-patients-prescribed-propro-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/demographic-and-clinical-characteristics-of-patients-prescribed-propro-peer-reviewed-article-TCRM

Similar Items